Hip Disease

8

Review clinical trials related to Hip Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Pericapsular Nerve Group Block Versus Intrathecal Morphine for Analgesia After Total Hip Arthroplasty

The Pericapsular Nerve Group (PENG) block is an effective method for postoperative pain management in patients undergoing primary total hip arthroplasty (THA) via a posterolateral approach. The application of this technique reduces postoperative opioid requirements, thereby limiting the risk of adverse effects associated with systemic opioid administration. Effective pain control and a reduced incidence of side effects may translate into higher patient satisfaction and a decreased length of hospital stay (LOS). The PENG block serves as an effective component of multimodal analgesia and may provide an alternative to intrathecal morphine in patients undergoing primary total hip arthroplasty via a posterolateral approach, where the primary anesthetic technique is spinal anesthesia with hyperbaric bupivacaine. Objectives 1. To evaluate the efficacy of the PENG block in postoperative pain control and compare its effectiveness with intrathecal morphine administration. 2. To assess the impact of the PENG block on postoperative opioid consumption in comparison to analgesia achieved via intrathecal morphine. 3. To analyze the incidence of selected adverse effects associated with systemic opioid administration in patients receiving a PENG block versus those in the intrathecal morphine group. 4. To evaluate patient satisfaction levels regarding postoperative pain management across the different analgesic modalities. 5. To analyze the correlation between the type of analgesia employed and the duration of hospitalization.

Participants needed: 180
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Medical University of GdanskUpdated: Mar 4, 2026
Eligibility criteria

Informed, written consent for study participation. [+6]

Absence of informed consent. [+9]

Status: Recruiting

Pediatric Orthopaedic Implant Safety & Efficacy

Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity. Given the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy. Prospective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).

Participants needed: 4,000
Trial details
Age: 0-25Biological sex: AllType: ObservationalSponsor: University of British ColumbiaUpdated: Nov 24, 2025Locations: 1Duration: 2 Years
Eligibility criteria

Patients indicated for the device-specific indication, per physician discretion... [+2]

Patients with a demonstrated sensitivity to metals [+1]

Status: Recruiting

ACE Acetabular Cup UK Multi-centre PMCF Study

A total hip replacement is one of the most successful and cost-effective surgical procedures in orthopaedics, and involves replacing both the hip ball and socket. Its goal is to provide pain relief, allowing the person to return to a normal lifestyle. JRI Orthopaedics have developed the ACE Acetabular Cup System, which has a H-A.C. coating to promote ossoeintegration of the device within the host bone. To increase the surgeons choice and thus suitability for the patient, there is the option of 3 different socket liners (ceramic, polymer or dual mobility). To ensure maximum safety and performance of medical devices surveillance of the device should be carried out over the devices lifetime. This study is a 10 year surveillance study to assess the clinical, functional and radiological outcomes of the CE-marked ACE Acetabular Cup System. This is done by examining patient outcomes through questionnaires, reviews of X-rays and complications by patients who have received a total hip replacement using the ACE Acetabular Cup System at participating sites.

Participants needed: 225
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: JRI OrthopaedicsUpdated: Sep 3, 2025Locations: 1
Eligibility criteria

Patients deemed suitable for elective primary THR, as per indications in the IFU... [+1]

Patients who are unable to provide written informed consent. [+5]

Status: Not yet recruiting

ACE Acetabular Cup Spanish PMCF Study

A total hip replacement is one of the most successful and cost-effective surgical procedures in orthopaedics, involving the replacement of both the hip ball and socket. Its goal is to provide pain relief and enable the patient to return to a normal lifestyle. JRI Orthopaedics have developed the ACE Acetabular Cup System, which has an H-A.C. coating to promote osseointegration of the device within the host bone. To increase the surgeon's choice and thus suitability for the patient, there is the option of three different socket liners (ceramic, polymer, or dual mobility). To ensure maximum safety and performance of medical devices, surveillance of the device should be carried out over the device's lifetime. This study is a 10-year surveillance study to assess the clinical, functional, and radiological outcomes of the CE-marked ACE Acetabular Cup System. This will be done by examining patient outcomes through questionnaires, reviews of X-rays, and recording any complications in patients who have received a total hip replacement using the ACE Acetabular Cup System at participating sites.

Participants needed: 120
Trial details
Age: 18-85Biological sex: AllType: ObservationalSponsor: JRI OrthopaedicsUpdated: Aug 29, 2025Locations: 1
Eligibility criteria

Patients deemed suitable for elective primary THR, as per indications in the IFU... [+1]

Patients who are unable to provide written informed consent. [+5]

Status: Recruiting

Effectiveness and Safety of the Electrically Powered Orthopedic Exercise Device on Gait Ability in Patients With Hip Joint Diseases

Gait is an essential daily activity performed through the complex coordination of the central and peripheral nervous systems and the musculoskeletal system. Gait disorders can negatively affect quality of life, increase the risk of falls, decrease the ability to perform daily activities, and limit physical activity. Various musculoskeletal diseases can cause gait impairment, with hip osteoarthritis and osteonecrosis of the femoral head (ONFH) being the most representative conditions. Various interventions can be attempted during the early stages of hip joint disease progression. However, improvement in symptoms does not necessarily indicate a halt in disease progression. As the condition advances in most patients, thinning of the full-thickness hip cartilage or collapse of the femoral head occurs, leading to restricted hip range of motion, weakness of the lower limb muscles and functional deterioration, resulting in the need for total hip arthroplasty. THA offers significant improvements in pain relief and function, regardless of the patient's preoperative status, and can reduce long-term healthcare costs. However, performing THA at an early stage with minimal functional improvement is not recommended. Postoperative complications, such as infections, aseptic loosening, and instability, are potential risks, with younger patients aged 45-64 showing higher revision surgery rates compared to those aged 65 and older. This highlights the need for new interventions that can delay the time to surgery while improving gait function and muscle strength. Therefore, this study aims to explore the clinical feasibility of the Angel Suit H10 (Angelrobotics, Seoul, Korea) by assessing whether wearing the Electrically Powered Orthopedic Exercise Device improves gait function in patients with hip joint diseases, along with evaluating user satisfaction and device safety.

Participants needed: 30
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Yonsei UniversityUpdated: Aug 29, 2025Locations: 1
Eligibility criteria

Individuals aged 19 or older [+6]

Individuals who have contraindications for lower limb weight-bearing such as sev... [+13]

Status: Recruiting

PENG With LFCB vs. ESP Blocks for Pediatric Hip Surgery

This randomized controlled trial (RCT) compares the analgesic effectiveness of two regional anesthesia techniques-Pericapsular Nerve Group (PENG) block combined with Lateral Femoral Cutaneous Nerve Block (LFCB) versus Lumbar and Sacral Erector Spinae Plane Blocks (L-ESPB and S-ESPB)-in pediatric patients undergoing hip surgery.

Participants needed: 60
Trial details
Phase: Phase 4Age: 2-16Biological sex: AllType: InterventionalSponsor: Poznan University of Medical SciencesUpdated: Jul 11, 2025Locations: 1
Eligibility criteria

Pediatric patients aged between 2 and 16 years. [+3]

Known allergy or hypersensitivity to any of the study medications [+6]

Status: Recruiting

MDR - PMCF Study for Taperloc Complete Stems

The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up\*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.

Participants needed: 820
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Zimmer BiometUpdated: Mar 11, 2025Locations: 3
Eligibility criteria

Patient must be 18 years of age or older and skeletally mature [+5]

Off-label use [+14]

Status: Recruiting

Everglade Stem, World Cup and World Liner Post Market Clinical Follow-up

The aim of the Study is to monitor the performance of the Signature Orthopaedics Everglade Stem, World Acetabular Cup and World Liner as a part of post-market vigilance and continuous improvement efforts.

Participants needed: 200
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Signature OrthopaedicsUpdated: Dec 1, 2023Locations: 1
Eligibility criteria

patient requires unilateral primary total hip arthroplasty due to non-inflammato... [+3]

patient has active infection or sepsis(treated or untreated) enough to compromis... [+6]